Trial Profile
A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Aug 2020
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pharmacyclics
- 01 Jul 2020 Results of analysis submitted to FDA assessing patient-reported outcomes data from this study published in the Quality of Life Research
- 14 Jun 2019 Status changed from active, no longer recruiting to completed.
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association